Vontobel Holding Ltd. Trims Stock Position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)

Vontobel Holding Ltd. trimmed its stake in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) by 3.2% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 29,735 shares of the biotechnology company’s stock after selling 989 shares during the quarter. Vontobel Holding Ltd. owned about 0.11% of Arcturus Therapeutics worth $690,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. CANADA LIFE ASSURANCE Co increased its stake in shares of Arcturus Therapeutics by 10.5% during the first quarter. CANADA LIFE ASSURANCE Co now owns 4,492 shares of the biotechnology company’s stock worth $152,000 after acquiring an additional 428 shares during the period. Hennion & Walsh Asset Management Inc. raised its stake in shares of Arcturus Therapeutics by 2.5% during the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 31,930 shares of the biotechnology company’s stock worth $1,078,000 after buying an additional 778 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in shares of Arcturus Therapeutics by 5.7% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 17,004 shares of the biotechnology company’s stock valued at $575,000 after buying an additional 922 shares during the period. Russell Investments Group Ltd. acquired a new stake in shares of Arcturus Therapeutics in the 1st quarter valued at approximately $40,000. Finally, Public Employees Retirement System of Ohio boosted its stake in shares of Arcturus Therapeutics by 63.8% in the first quarter. Public Employees Retirement System of Ohio now owns 4,620 shares of the biotechnology company’s stock valued at $156,000 after buying an additional 1,800 shares in the last quarter. 94.54% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Arcturus Therapeutics news, COO Pad Chivukula sold 12,000 shares of the company’s stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $20.76, for a total value of $249,120.00. Following the transaction, the chief operating officer now directly owns 435,334 shares in the company, valued at approximately $9,037,533.84. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 13.80% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several research analysts have issued reports on ARCT shares. Leerink Partnrs upgraded Arcturus Therapeutics to a “strong-buy” rating in a research report on Monday, August 12th. Leerink Partners assumed coverage on shares of Arcturus Therapeutics in a research note on Monday, August 12th. They issued an “outperform” rating and a $70.00 price objective for the company. Cantor Fitzgerald reissued an “overweight” rating on shares of Arcturus Therapeutics in a report on Monday, September 9th. Finally, HC Wainwright reiterated a “buy” rating and set a $63.00 price target on shares of Arcturus Therapeutics in a research report on Tuesday, October 1st. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $71.40.

Arcturus Therapeutics Trading Down 1.3 %

Shares of ARCT opened at $20.88 on Tuesday. Arcturus Therapeutics Holdings Inc. has a 12-month low of $17.52 and a 12-month high of $45.00. The stock has a market cap of $562.34 million, a P/E ratio of -5.34 and a beta of 2.61. The company has a 50-day moving average of $21.19 and a two-hundred day moving average of $25.25.

Arcturus Therapeutics (NASDAQ:ARCT) last issued its quarterly earnings data on Monday, August 5th. The biotechnology company reported ($0.64) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.85) by $1.21. The firm had revenue of $49.86 million during the quarter, compared to the consensus estimate of $21.00 million. Arcturus Therapeutics had a negative return on equity of 25.47% and a negative net margin of 41.21%. During the same period in the previous year, the firm posted ($1.98) EPS. As a group, analysts forecast that Arcturus Therapeutics Holdings Inc. will post -2.6 EPS for the current fiscal year.

Arcturus Therapeutics Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.